Pharmacoeconomic review report : Tenofovir alafenamide (Vemlidy) (Gilead Sciences Canada, Inc.)

Pharmacoeconomic review report Tenofovir alafenamide (Vemlidy) (Gilead Sciences Canada, Inc.)

Tenofovir alafenamide (TAF, Vemlidy) is a prodrug of tenofovir, which is indicated for the treatment of chronic hepatitis B (HBV) in adults with compensated liver disease. The manufacturer submitted a price of 19.55 per 25 mg tablet, which, at the recommended dose of 25 mg daily, costs 19.55 per pat...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2018.
Colección:Common drug review clinical review report.
Materias:
Drug interactions.
Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820267606719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of the Economic Analysis Submitted by the Manufacturer
  • Key Limitations
  • Results / Conclusions
  • Cost Comparison Table
  • Appendix 1. Price Reduction Analysis
  • Appendix 2. Reviewer Worksheets
  • References.

Ejemplares similares